drugset / Trial / NCT05559450
Blinatumomab as a Bridge to Allo-HSCT in HR BCP-ALL
Phase 2
Unknown
80 enrolled
The First Affiliated Hospital of Soochow University
First Affiliated Hospital of Wannan Medical College · collabFujian Medical University Union Hospital · collabThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · collabThe First People's Hospital of Changzhou · collabWuxi People's Hospital · collabZhongda Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
To explore the efficacy and safty of Blinatumomab as a bridge to Allogeneic Hematopoietic Stem Cell Transplantation in High Risk Precursor B-cell Acute Lymphoblastic Leukemia
Timeline
- Start
- 2022-02-01
- Primary completion
- 2024-01-01
- Completion
- 2026-01
Publications
- Background Gokbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, Diedrich H, Topp MS, Bruggemann M, Horst HA, Havelange V, Stieglmaier J, Wessels H, Haddad V, Benjamin JE, Zugmaier G, Nagorsen D, Bargou RC. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018 Apr 5;131(14):1522-1531. doi: 10.1182/blood-2017-08-798322. Epub 2018 Jan 22.
- Davis KL, Yao CC, Zimmerman JAO, Rau RE. Immunotherapy in B-Cell Acute Lymphoblastic Leukemia. J Natl Compr Canc Netw. 2025 Dec;23(12):e257067. doi: 10.6004/jnccn.2025.7067.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Blinatumomab | Monoclonal antibody | 15 ug/m2 | Intravenous |
| Subject | Blinatumomab | Monoclonal antibody | 28 ug | Intravenous |